TY - JOUR T1 - ▼ Empagliflozin, diabetes and outcomes JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 78 LP - 81 DO - 10.1136/dtb.2016.6.0411 VL - 54 IS - 7 A2 - , Y1 - 2016/07/01 UR - http://dtb.bmj.com/content/54/7/78.abstract N2 - The prevalence of type 2 diabetes is rising, and in 2015 more than 5% of adults in the UK were affected by this condition.1,2 Management of type 2 diabetes includes encouraging lifestyle changes (increased exercise, modification of diet and smoking cessation) alongside the provision of medication to minimise long-term complications and manage blood sugar control while avoiding unwanted effects of drug treatment.3 Of particular importance, people with type 2 diabetes are at increased risk of cardiovascular disease, and therefore the aims of treatment also include modification of associated risk factors.2-5▼ Empagliflozin (Jardiance-Boehringer Ingelheim) is the third sodium-glucose co-transporter-2 (SGLT2) inhibitor licensed for use in the UK. It was launched in August 2014, and acts in a similar way to the other SGLT2 inhibitors, ▼ dapagliflozin and ▼ canagliflozin, by inhibiting renal glucose resorption and promoting glycosuria.6 It is indicated for the treatment of type 2 diabetes in adults to improve glycaemic control, as monotherapy when metformin cannot be used, and in combination with other glucose-lowering drugs including insulin. Here we review the evidence for empagliflozin and discuss the results of a recent study that assessed cardiovascular outcomes. ER -